X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Health & Nutrition

Nestle unveils science-backed innovation for early-life nutrition

Content Team by Content Team
13th January 2024
in Health & Nutrition, News
Nestle unveils science-backed innovation for early-life nutrition

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Nestlé has unveiled Sinergity, a blend that combines a probiotic with six human milk oligosaccharides (HMOs) to support age-adapted infant development.

For years, Nestlé has been understanding the the composition of various nutrients and bioactives that are present in breastmilk such as proteins and HMOs.

The company has reported how a specific strain (B. infantis LMG11588) has the ability to efficiently absorb and metabolise HMOs, producing key beneficial compounds, in addition to the direct benefits already provided by the HMOs and the probiotic individually.

Nestlé says that the combination of these elements creates a “synergistic effect,” resulting in a dominance of bifidobacteria which can lead to a more favourable gut environment and stronger immunity in infants.

Building on its expertise, Nestlé has developed the new Sinergity proprietary blend containing an infant-specific probiotic strain along with a blend of HMOs.

As research shows that the composition of HMOs in breastmilk changes during the lactation period, products containing the new blend have varying levels of six different HMOs to meet the specific needs of infants according to age.

Laurent Alsteens, global head of early childhood nutrition at Nestlé, said: “We are absolutely committed to engaging in groundbreaking research and are working with healthcare professionals to contribute to optimal nutrition in early childhood through clinically tested solutions that provide the essential nutrients for babies that cannot be exclusively or who are only partially breastfed. In this way, we can help advance breakthrough nutritional solutions for infants with ingredient blends to support age-appropriate growth, digestive health, bone, muscle and cognitive development and the immune system.”

Isabelle Bureau-Franz, head of Nestlé’s R&D for nutrition, added: “Thanks to our continuous scientific advancements, we have discovered the important benefits of combining our proprietary B. infantis probiotic with a blend of six HMOs. Leveraging our innovation expertise, we developed this breakthrough solution by successfully translating the new scientific findings, scaling-up the production of the probiotic and carefully adapting the levels of six HMOs according to age.”

The new blend has been launched in Hong Kong, with rollout Latin America expected towards the end of the year and in Europe early next year.

The news follows the announcement earlier this week that Nestlé is to shut down its infant formula facility and co-located R&D centre in County Limerick, Ireland, stating that “external trends” have impacted the demand for infant nutrition products in Greater China. Also this week, the company unveiled its first “affordable and nutritious” instant powder in Central and West Africa, combining milk and locally sourced soy, containing essential nutrients such as protein and fibre and providing a source of iron and calcium.

Previous Post

Danone enters adult medical nutrition category in China

Next Post

Rheonix Inc Publishes Cyclospora cayetanensis Data in Collaboration With FDA Center for Food Safety and Applied Nutrition

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Rheonix Inc Publishes Cyclospora cayetanensis Data in Collaboration With FDA Center for Food Safety and Applied Nutrition

Rheonix Inc Publishes Cyclospora cayetanensis Data in Collaboration With FDA Center for Food Safety and Applied Nutrition

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In